Johnson & Johnson acquired Ambrx Biopharma for approximately $2.0 billion ($28.00 per share) in an all-cash merger announced January 8, 2024 and completed March 7, 2024, gaining a proprietary synthetic biology technology platform for designing next-generation antibody-drug conjugates (ADCs) and clinical candidates targeting prostate cancer, breast cancer, and renal cell carcinoma. The lead asset, anti-PSMA ADC ARX517, has since been advanced under J&J nomenclature as JNJ-95298177; its first-in-human APEX-01 study (NCT04662580) was expanded to evaluate combination with androgen-receptor pathway inhibitors and is now active and not recruiting, with estimated study completion in December 2026.
Key facts
AnnouncedJan 08, 2024
ClosedMar 07, 2024
Deal value$2.0B
Deal typeAcquisition/Merger
Therapeutic areaOncology
IndicationsMetastatic Castration-Resistant Prostate Cancer, HER2-Positive Breast Cancer, Renal Cell Carcinoma